Rallybio: RLYB212 Phase 1b rapidly eliminates HPA-1a platelets; proof-of-concept data Q1 2023

Rallybio Corp

RLYB212 showed >90% reduction in mean platelet elimination half-life vs placebo in Phase 1b.
Single subcutaneous dose eliminated transfused HPA-1a positive platelets rapidly one week after dosing.
No serious adverse events; safety and tolerability acceptable.
Protocol amended to increase dose and expand PK/PD sampling; registrational trial dosing expected to be informed.
Proof-of-concept data from Phase 1b study expected in Q1 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.